Literature DB >> 29556021

A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.

Daichi Inoue1, Takeshi Fujino2, Paul Sheridan3, Yao-Zhong Zhang3, Reina Nagase2, Sayuri Horikawa2, Zaomin Li4, Hirotaka Matsui5, Akinori Kanai6, Makoto Saika2, Rui Yamaguchi3, Hiroko Kozuka-Hata7, Kimihito Cojin Kawabata2, Akihiko Yokoyama8, Susumu Goyama2, Toshiya Inaba6, Seiya Imoto3, Satoru Miyano3, Mingjiang Xu4, Feng-Chun Yang4, Masaaki Oyama7, Toshio Kitamura9.   

Abstract

ASXL1 plays key roles in epigenetic regulation of gene expression through methylation of histone H3K27, and disruption of ASXL1 drives myeloid malignancies, at least in part, via derepression of posterior HOXA loci. However, little is known about the identity of proteins that interact with ASXL1 and about the functions of ASXL1 in modulation of the active histone mark, such as H3K4 methylation. In this study, we demonstrate that ASXL1 is a part of a protein complex containing HCFC1 and OGT; OGT directly stabilizes ASXL1 by O-GlcNAcylation. Disruption of this novel axis inhibited myeloid differentiation and H3K4 methylation as well as H2B glycosylation and impaired transcription of genes involved in myeloid differentiation, splicing, and ribosomal functions; this has implications for myelodysplastic syndrome (MDS) pathogenesis, as each of these processes are perturbed in the disease. This axis is responsible for tumor suppression in the myeloid compartment, as reactivation of OGT induced myeloid differentiation and reduced leukemogenecity both in vivo and in vitro. Our data also suggest that MLL5, a known HCFC1/OGT-interacting protein, is responsible for gene activation by the ASXL1-OGT axis. These data shed light on the novel roles of the ASXL1-OGT axis in H3K4 methylation and activation of transcription.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29556021     DOI: 10.1038/s41375-018-0083-3

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  19 in total

Review 1.  Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Authors:  Shuhei Asada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2018-12-05       Impact factor: 2.490

Review 2.  JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy.

Authors:  Michele Ciboddo; Ann Mullally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.

Authors:  Xiaona You; Fabao Liu; Moritz Binder; Alexis Vedder; Terra Lasho; Zhi Wen; Xin Gao; Evan Flietner; Adhithi Rajagopalan; Yun Zhou; Christy Finke; Abhishek Mangaonkar; Ruiqi Liao; Guangyao Kong; Erik A Ranheim; Nathalie Droin; Anthony M Hunter; Sergey Nikolaev; Maria Balasis; Omar Abdel-Wahab; Ross L Levine; Britta Will; Kalyan Vara Ganesh Nadiminti; David Yang; Klaus Geissler; Eric Solary; Wei Xu; Eric Padron; Mrinal M Patnaik; Jing Zhang
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

4.  O-GlcNAcylation homeostasis controlled by calcium influx channels regulates multiple myeloma dissemination.

Authors:  Parinya Samart; Sudjit Luanpitpong; Yon Rojanasakul; Surapol Issaragrisil
Journal:  J Exp Clin Cancer Res       Date:  2021-03-16

Review 5.  Multiple Roles of Glycans in Hematological Malignancies.

Authors:  Xingchen Pang; Hongjiao Li; Feng Guan; Xiang Li
Journal:  Front Oncol       Date:  2018-09-06       Impact factor: 6.244

6.  ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells.

Authors:  Daichi Inoue; Takeshi Fujino; Toshio Kitamura
Journal:  Oncotarget       Date:  2018-10-16

7.  Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia.

Authors:  K M Kampa-Schittenhelm; T Haverkamp; M Bonin; V Tsintari; H J Bühring; L Haeusser; G Blumenstock; S T Dreher; T Ganief; F Akmut; B Illing; U A Mau-Holzmann; I Bonzheim; E Schleicher; W Vogel; M M Schittenhelm
Journal:  EBioMedicine       Date:  2020-04-06       Impact factor: 8.143

8.  Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.

Authors:  Reina Nagase; Daichi Inoue; Alessandro Pastore; Takeshi Fujino; Hsin-An Hou; Norimasa Yamasaki; Susumu Goyama; Makoto Saika; Akinori Kanai; Yasuyuki Sera; Sayuri Horikawa; Yasunori Ota; Shuhei Asada; Yasutaka Hayashi; Kimihito Cojin Kawabata; Reina Takeda; Hwei-Fang Tien; Hiroaki Honda; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Exp Med       Date:  2018-04-11       Impact factor: 14.307

9.  A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.

Authors:  Osamu Imataki; Tomoya Ishida; Hiroyuki Kubo; Makiko Uemura; Yasuhito Nanya; Kimihiro Kawakami; Seishi Ogawa; Norimitsu Kadowaki
Journal:  Case Rep Oncol       Date:  2020-04-22

10.  Hcfc1a regulates neural precursor proliferation and asxl1 expression in the developing brain.

Authors:  Victoria L Castro; Joel F Reyes; Nayeli G Reyes-Nava; David Paz; Anita M Quintana
Journal:  BMC Neurosci       Date:  2020-06-10       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.